Introduction
Adipose tissue is not only a simple energy storage depot but an important endocrine organ. The role of adipose tissuederived hormones as pivotal regulators of whole-body lipid and glucose metabolism gains more and more of importance.
The adipokine adiponectin was found to enhance the effect of insulin on hepatic gluconeogenesis, accelerates peripheral free fatty acid uptake and induces b-oxidation in skeletal muscle and liver. In addition, adiponectin acts as an anti-inflammatory and antiatherogenic agent by diminishing monocyte adhesion to the endothelium, decreasing smooth muscle cell proliferation and reducing foam cell formation (for review, see Chandran et al 1 ). All these effects are postulated to be mediated by the recently cloned adiponectin receptors AdipoR1 and AdipoR2. 2 Importantly, the skeletal muscle expression levels of both receptors were shown to be associated with insulin sensitivity and family history of type 2 diabetes. 3 Hyperinsulinemia, as provoked by hyperinsulinemic-euglycemic clamp, increased the AdipoR1 mRNA content of skeletal muscle two-fold. 4 With regard to pharmacological regulation of AdipoR expression, a recent publication reports significant induction of AdipoR2 gene expression by the thiazolidinedione (TZD) rosiglitazone and the fibrate Wy-14,643 in human macrophages. 5 TZDs are the most potent triggers of adipose differentiation and were found to be direct and high-affinity ligands of PPARg. [6] [7] [8] Furthermore, in vitro and ex vivo studies have consistently shown that TZDs improve insulin sensitivity in all major insulin-responsive tissues including skeletal muscle. 9 Fibrates, acting as PPARa activators, are used therapeutically as potent hypolipidemic agents, 10 and new evidences suggest that they might also prove effective for treating obesity and insulin resistance 11 and for reducing the progression of atherosclerosis.
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With regard to the improving effects of TZDs and fibrates on insulin resistance and the inductive effect of these agents on AdipoR2 gene expression in human macrophages, the aim of this study was to test whether adiponectin receptors are also positively modulated by PPARg and PPARa agonists in human skeletal muscle cells, a cell type crucial for wholebody insulin sensitivity.
Materials and methods
Tissue sampling and cell culture Primary human skeletal muscle cells were grown from satellite cells obtained from percutaneous needle biopsies performed on the lateral portion of the quadriceps femoris (vastus lateralis) muscle as recently described in detail. 13 The donors were normal weight nondiabetic Caucasian subjects (four women/six men, age 25.771.6 y, BMI 23.171.1 kg/m 2 , mean7s.e.) recruited from the Tuebinger Family Study for type 2 diabetes and gave informed written consent prior to the biopsy. Subcultured (first pass) cells, after growth to 80-90% confluence, were differentiated into myotubes as described previously. 13 On day 5 of differentiation, fresh medium containing troglitazone, rosiglitazone, Wy-14,643, fenofibrate, or DMSO (for vehicle control), respectively, was added to the cells at the indicated concentrations. The cells then were incubated for up to 20 h prior to RNA analysis. In one experimental setting, troglitazone was administered during the complete 5-day differentiation period. The study was approved by the local ethical committee.
RT-PCR
RNA was isolated with RNeasy Mini Kit according to the manufacturer's instructions (Qiagen, Hilden, Germany). Total RNA treated with RNase-free DNase I was transcribed into cDNA using AMV reverse transcriptase and first-strand cDNA kit from Roche Diagnostics (Mannheim, Germany).
Quantitative PCR was performed with SYBR Green I dye on a high-speed thermal cycler with integrated microvolume fluorometer according to the instructions of the manufacturer. We used primers from Invitrogen (Karlsruhe, Germany). The PCR conditions are given in Table 1 . All measurements were performed in triplicates.
Statistics
Data were analyzed by the nonparametric Wilcoxon signed rank test and differences were considered significant when Po0.05.
Results
We treated fully differentiated human myotubes with troglitazone (10 mM) for 20 h (n ¼ 11). To assess the effectiveness of troglitazone, we measured PPARg and D-6 desaturase gene expression of differentiated myotubes. Consistent with earlier results, 14, 15 troglitazone treatment resulted in a significant 1.8-fold induction of PPARg gene expression (n ¼ 11, P ¼ 0.00098) ( Figure 1a ) and a 55% reduction of D-6 desaturase in human myotubes (not shown). Having proven the effectiveness of troglitazone, we studied modulating effects of troglitazone on mRNA expression of AdipoR1 and AdipoR2 in human myotubes. mRNA expression of both receptors tended to decrease by treatment with troglitazone. AdipoR1 was reduced by 13% and AdipoR2 by 22%. These effects, however, did not reach the level of significance (Figure 1b and c) . Furthermore, we studied myotubes treated with troglitazone during the 5-day differentiation period, as described earlier. 16 In this experimental setting, we found identical results (data not shown).
In addition, we then treated differentiated myotubes with Wy-14,643 (10 mM) for 20 h and detected a significant twofold induction of PDHK4 gene expression compared to control conditions (n ¼ 9, P ¼ 0.00391) (Figure 2a) . As described earlier, PDHK4 is a target gene of PPARa in skeletal muscle cells. 17 However, treatment with Wy-14,643 did not have a significant regulatory impact on either AdipoR1 or AdipoR2 gene expression in differentiated myotubes ( Figure  2b and c).
To examine whether troglitazone or Wy-14,643 (10 mM each) exert short-term effects on AdipoR expression, we conducted time courses (0-20 h). As compared to the vehicle control, neither troglitazone nor Wy-14,643 significantly affected AdipoR1 (Figure 3a) and AdipoR2 (Figure 3b ) mRNA expression at any time point tested. To test whether the lack of effects is restricted to these two compounds only or is specific for the TZD and the fibrate classes of drugs, we performed dose-response experiments with troglitazone (1-10 mM), rosiglitazone (0.1-1 mM), Wy-14,643 (1-10 mM), and Regulation of adiponectin receptor gene expression S Kaltenbach et al fenofibrate (6-60 mM). As depicted in Figure 4 , none of these compounds exerted significant effects on AdipoR1 and AdipoR2 mRNA expression at any concentration tested.
Discussion
Insulin-sensitizing effects of TZDs on peripheral insulinresponsive tissues are thought to be direct for example by altering glucose metabolism in skeletal muscle cells 18, 19 and indirect by altering lipid metabolism and hormon production in adipose tissue. [20] [21] [22] For the adipokine TNF-a, it was shown that TZDs block TNFa's inhibitory effect on insulinstimulated glucose uptake as well as TNFa gene expression in 3T3-L1 cells, and a study in diabetic mice revealed a normalizing effect of the TZD pioglitazone on overexpression of both TNFa receptors TNFR1 and TNFR2. 23, 24 Furthermore PPARg activation by TZDs inhibits leptin expression in vivo and in vitro. 
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Moreover, adiponectin gene expression in adipocytes as well as serum adiponectin concentration were found to be increased after TZD treatment. 19 We show here that treatment with troglitazone and rosiglitazone, although modulating expression of known PPARg target genes, such as PPARg itself and D-6 desaturase, 14, 15 does not induce mRNA expression of AdipoR1 and AdipoR2 in human skeletal muscle cells. This is in apparent contrast to recently published data showing induction of AdipoR2 by PPARg agonists rosiglitazone and GW929 in human macrophages. 5 PPARa agonists are used as hypolipidemic agents. 10 Investigations on PPARa-mediated effects on the skeletal muscle revealed enhancement of b-oxidation and decrease of fatty acid esterification into myocyte triacyglycerol. 12 At the gene expression level, induction of PDHK4 mRNA expression in human skeletal muscle cells 17 and induction of AdipoR2 gene expression in human macrophages was observed after treatment with PPARa agonists. 5 By contrast, our results
show that the PPARa agonists Wy-14,643 and fenofibrate, although significantly inducing PDHK4 gene expression, do not modulate AdipoR1 and AdipoR2 gene expression in human skeletal muscle cells. Therefore, we suggest that TZDs and fibrates do not enhance adiponectin signaling and do not exert their insulin-sensitizing and lipid-lowering effects by modulating adiponectin receptor expression in skeletal muscle cells. The reasons for this divergence to macrophages might be cell type-inherent and due to differences in the expression of transcriptional cofactors such as PGC1.
In summary, we show here that PPARg and PPARa agonists do not regulate mRNA expression of AdipoR1 and AdipoR2 in human myotubes. Therefore, we conclude that induction of adiponectin receptor gene expression in human skeletal muscle cells is not involved in the insulin-sensitizing effects of TZDs and the lipid-lowering effects of fibrates.
